Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a repurchase of 26,000 H-shares on 20 May 2026, which have been retained as treasury shares. The on-market buyback was executed within a price range of HKD 28.94 to HKD 30.48 per share, translating into a volume-weighted average cost of HKD 29.47 per share and an aggregate cash outlay of HKD 0.77 million.

Post-transaction, the company’s outstanding share count (excluding treasury shares) fell to 135.48 million, down 0.02% from 135.51 million a day earlier. The total issued share capital remains unchanged at 136.22 million shares, while treasury shares increased to 735,000.

The repurchase forms part of the mandate approved on 12 February 2026, under which Hanx Biopharmaceuticals is authorised to buy back up to 13.62 million shares. Including the latest transaction, the company has repurchased 735,000 shares, representing approximately 0.54% of the issued share base on the mandate date.

In accordance with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on issuing new shares or selling treasury shares, ending on 19 June 2026.